Associated Papers
Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
Murakami S et al.
Thoracic Cancer, 2022
Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L et al.
International Journal of Clinical and Experimental Pathology, 2020
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
Kim EY et al.
Cancer Biology & Therapy, 2016
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
Vignot S et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2013
Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.
Kerner GS et al.
Plos One, 2013
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.
An SJ et al.
Plos One, 2012
Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients.
Chiou CC et al.
Cancer Genomics & Proteomics, 0
Select a paper to view details